In vivo nano-engineering of T cells has moved from a delivery question to an integrated framework that combines targeting, exposure, and expression to build CAR T therapies within patients.
First-pass extracted concept
in vivo nano-engineering of T cells for CAR-T therapy
Candidate: concept label1 source documents3 linked claims
Live refresh every 5sNext refresh in 5s
Evidence Snippets
Supporting Sources
Linked Claims
In vivo nano-engineering of T cells for CAR-T therapy is presented as an integrated framework combining targeting, exposure, and expression rather than only a delivery problem.
Active targeting on viral and nonviral carriers depends on ligand architecture, avidity, linker chemistry, and endosomal escape, while practical constraints include variable EPR, off-targeting, and batch consistency.
The source advocates coordinated design of active targeting, corona-aware exposure, and expression-centric control for scalable, indication-tailored in vivo CAR-T development, with translational priorities in targeting precision, analytics and CMC, and regulatory classification.